Health News Releases

  • Today October 6
PCI becomes first drug product CDMO to navigate ICMRA multi-agency inspection process. (Photo: Busin
August 22, 14:05
PCI Pharma Services’ Bedford, New Hampshire Location Successfully Completes International Coalition of Medicines Regulatory Authorities Inspection
PCI Pharma Services (PCI), a leading global contract development and manufacturing organization (CDMO), has successfully completed the International Coalition of Medicines Regulatory Authorities (ICMR
August 21, 14:45
Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets
Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, announced it has expanded its agreement with Eli Lilly and Company (Lilly) to become the sole distributor and promoter
August 20, 15:55
Guard Medical Announces FDA 510(k) Clearance for Additional Large Sizes of Its Novel NPseal® NPWT Surgical Dressing, Unlocking the Orthopedic Market
Privately-held company Guard Medical Inc. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.guard-medical.com%2F&esheet=54110779&newsitemid=20240819281623&lan=en-US&anchor=Guard+Me
HistoSonics Edison® Histotripsy System (Photo: Business Wire)
August 16, 15:40
HistoSonics Announces Oversubscribed $102 Million Series D Financing to Scale Launch of Non-Invasive Histotripsy Platform
HistoSonics (https://histosonics.com/), the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, announced today the completion of an oversubscribed $102 million Ser
Vector-borne diseases account for more than 17% of all infectious diseases, causing more than 700 00
August 15, 10:25
Bio-Gene and Envu Collaborate to Evaluate Flavocide™ for Use in Public and Private Sector Mosquito Management
Bio-Gene Technology Limited (ASX:BGT or ‘Bio-Gene’), an Australian company developing the next generation of novel bio-insecticides, and Envu are evaluating Flavocide™ for use in professional pest man
Everest Group Life Sciences and Medical Affairs Operations PEAK Matrix® Assessment 2024 (Graphic: Bu
August 14, 10:40
Freyr Recognized as a Leader in Everest Group PEAK Matrix® 2024
Freyr, a premier global Regulatory solutions and services provider, proudly announces its distinguished placement as a Leader in the esteemed Everest Group Life Sciences Regulatory and Medical Affairs
August 13, 16:19
Galderma Receives U.S. FDA Approval for Nemluvio® (nemolizumab) for Adult Patients Living With Prurigo Nodularis
Galderma today announced that the U.S. Food and Drug Administration (FDA) has approved Nemluvio® (nemolizumab) as a pre-filled pen for subcutaneous injection for the treatment of adults with prurigo n
August 13, 14:53
Brandnew Lab Concludes Successful Symposium for NUVOEN Launch
On August 13, Brandnew Lab (https://brandnewlab.co.kr) announced the successful launch of its highly anticipated clinical-use ampoule line, NUVOEN, at the symposium that took place on July 22 at the B
Bifidobacterium infantis M-63 is a unique probiotic strain of human-residential bifidobacteria (HRB)
August 11, 09:45
Morinaga Milk Obtains the Registration of “New Food Ingredient” in China for use of its Probiotic Bifidobacterium infantis M-63 in Infant Foods
Morinaga Milk Industry Co., Ltd. (https://www.morinagamilk.co.jp/english/) (TOKYO:2264), a leading Japanese dairy product company, today announced its proprietary probiotic Bifidobacterium infantis M-
August 09, 15:35
Parse Biosciences Partners with Taiwan-based Prisma Biotech to Extend Reach in Asia
Parse Biosciences (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.parsebiosciences.com%2F&esheet=54104966&newsitemid=20240807623635&lan=en-US&anchor=Parse+Biosciences&index=1&md
The Nichi BRITE Beta 1,3-1,6 Glucan is produced as an exo-polysaccharide by Aureobasidium Pullulans
August 09, 15:10
Nichi BRITE Beta glucan as an onco-nutrition supplement in pancreatic cancer; Encouraging clinical results reported by Chikamori Hospital, Japan.
Nichi BRITE Beta glucan administration resulted in enhancement of immunity followed by reduction in biomarkers of pancreatic cancer and that of its recurrence in patients undergoing surgical resection
(Graphic: Business Wire)
August 09, 15:00
BeiGene Enters Next Phase of Global Growth with Announcement of Second Quarter 2024 Financial Results and Corporate Updates
BeiGene (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.beigene.com%2F&esheet=54105663&newsitemid=20240807337131&lan=en-US&anchor=BeiGene&index=1&md5=66784fdcb48f17570d0bd05940b
August 08, 15:25
Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54104396&newsitemid=20240806343138&lan=en-US&anchor=TSE%3A4
August 05, 14:39
Galderma to pursue a new scientific partnership with L’Oréal to further advance its category leadership in dermatology
Galderma today announced that it has signed a memorandum of understanding with L’Oréal to work towards a new research and development (R&D) collaboration in the form of a scientific partnership focuse
August 02, 09:40
In-Depth Report on Global Oesophageal Cancer Clinical Trials Now Available
Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, ha
Representatives from Boston Oncology and King Fahd Medical City (KFMC), along with His Excellency En
August 01, 15:30
Boston Oncology and King Fahd Medical City (KFMC) Partner to Advance Localized Cell & Gene Therapy in Saudi Arabia
In a landmark initiative poised to transform healthcare in the Kingdom of Saudi Arabia, Boston Oncology and King Fahd Medical City (KFMC) have signed a Letter of Intent to collaborate on the localizat
August 01, 14:30
Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody/ADC therapeutics, announced that it has entered into an o
August 01, 14:00
Takeda Announces First Quarter FY2024 Results - Strong Performance by Growth & Launch Products; Advancements in Promising Late-Stage Pipeline
Takeda (TOKYO:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&esheet=54099945&newsitemid=20240725145481&lan=en-US&anc
(Photo: Business Wire)
July 31, 11:40
Carestream Wins Renowned Award for Dental Films
We’re excited to announce Carestream recently received the Health Leaders Award in the Dental Category from Grupo Mídia in Brazil, a renowned international multimedia company. This distinguished aw
July 31, 10:45
Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease
Biogen Inc. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.biogen.com&esheet=54101572&newsitemid=20240730216833&lan=en-US&anchor=Biogen+Inc.&index=1&md5=4c98be33119620eca3992544
Shield is a blood test from Guardant Health for colorectal cancer screening in average-risk individu
July 30, 15:15
Guardant Health’s Shield™ Blood Test Approved by FDA as a Primary Screening Option, Clearing Path for Medicare Reimbursement and a New Era of Colorectal Cancer Screening
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the U.S. Food and Drug Administration (FDA) has approved the company’s Shield™ blood test for colorectal cance
July 30, 14:32
Galderma’s Relfydess™ (RelabotulinumtoxinA) Receives Positive Decision for Use in Europe
Galderma today announced that it has completed its European decentralized procedure (DCP), resulting in a positive decision for Relfydess™ (RelabotulinumtoxinA - previously referred to as QM1114). Rel
July 30, 11:45
Eisai Selects Medidata’s Clinical Data Studio to Enhance and Modernize Clinical Trial Efficiency and Patient Experience
Medidata (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.medidata.com%2Fen%2F&esheet=54098752&newsitemid=20240724837236&lan=en-US&anchor=Medidata&index=1&md5=67239cebded0696c115
July 28, 10:50
Fujirebio Launches the Fully Automated Lumipulse® G GFAP Assay for Research Use Only and Further Strengthens its Neuro Test Menu
H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G GFAP assay for the fully automated, random-access LUMIPULSE® G immunoassay system
July 25, 17:25
Galderma Delivers Record Net Sales of 2.2 Billion USD and 10.8% Year-on-Year Growth at Constant Currency for the First Half of 2024
Galderma Group AG, the pure-play dermatology category leader, today announced its financial results for the first half of 2024. · Record net sales of 2.2 billion USD in the first half of 2024, with
July 25, 15:31
PHASE III ARCADIA 1 and 2 Trial Primary Results Published in The Lancet: Galderma’s Nemolizumab Improves Key Aspects of Atopic Dermatitis - Itch, Skin Lesions and Sleep Disturbance
Galderma today announced that full results from the phase III ARCADIA 1 and 2 clinical trials in atopic dermatitis were published in The Lancet (https://cts.businesswire.com/ct/CT?id=smartlink&url=htt
Pearl, the global leader in dental AI, today announced that it has raised $58 million in Series B fu
July 25, 14:30
Pearl Raises Largest-Ever Investment in Dental AI with $58 Million Round
Pearl (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fhellopearl.com%2F%3Futm_campaign%3DPress%2520Releases%26utm_source%3Dlink&esheet=54098764&newsitemid=20240724200226&lan=en-US&a
July 25, 10:00
Following a Successful FDA Inspection, KBI Biopharma Extends and Expands Commercial Contract with Leading Global Pharmaceutical Company
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and global cGMP contract development and manufacturing organization (CDMO), today announced that it has extended and expanded its manufacturing c
BeiGene's flagship biologics manufacturing facility and clinical R&D center at the Princeton West I
July 24, 13:45
BeiGene Opens Flagship U.S. Biologics Manufacturing and Clinical R&D Facility, Continues Global Expansion to Deliver Medicines to More Patients Around the World
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the opening of its flagship U.S. facility in Hopewell, N.J., at the Princeton West Innovation Campus,
July 21, 10:25
MicroVention Announces Settlement Against Former Employees for Trade Secret Misappropriation and Breach of Contract Among Other Claims
MicroVention, a fully owned subsidiary of Terumo Corporation, announced today that the United States District Court for the Central District of California has issued an injunction permanently enjoinin
July 19, 15:10
BeiGene Announces Appointment of Aaron Rosenberg as Chief Financial Officer
BeiGene (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.beigene.com%2F&esheet=54096137&newsitemid=20240718157915&lan=en-US&anchor=BeiGene&index=1&md5=7fb29a782461d2203a45fc454af
Hanyang University’s Digital Healthcare Center and MIT Media Lab Sign MOU on Research Collaborations
July 19, 14:30
Hanyang University’s Digital Healthcare Center and MIT Media Lab Sign MOU to Jointly Develop Proposals for Research Collaborations
On July 8, Hanyang University’s Digital Healthcare Center signed a memorandum of understanding (MOU) with the Massachusetts Institute of Technology (MIT) Media Lab in Cambridge, Massachusetts, USA, to
July 19, 10:30
Brandnew Lab to Host Symposium on New Clinic-Use Ampoule ‘Nuvoen’
Brandnew Lab will be holding a symposium on July 22nd at the Brandnew Clinic in Cheongdam to introduce its new line of clinic-use ampoules, ‘NUVOEN’. At the symposium, Dr. Yoon Song Eun, the direct
July 17, 14:50
SOTIO Enters into Multi-Target Antibody Agreement with Biocytogen to Expand ADC Pipeline
SOTIO Biotech (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.sotio.com%2F&esheet=54094919&newsitemid=20240716652691&lan=en-US&anchor=SOTIO+Biotech&index=1&md5=279e5245d8e335ff5
July 12, 15:20
ILJIN SNT Co., Ltd. Calls on Board of Aurinia Pharmaceuticals to Honor Shareholders’ Voices Expressed at the AGM
ILJIN SNT Co., Ltd. (“ILJIN”), one of the largest shareholders of Aurinia Pharmaceuticals (NASDAQ: AUPH) (“Aurinia” or the “Company”), today issued an open letter to fellow shareholders. The full text
July 12, 11:30
Parse Biosciences Launches Certified Service Provider Program
Parse Biosciences (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.parsebiosciences.com%2F&esheet=54093141&newsitemid=20240711445815&lan=en-US&anchor=Parse+Biosciences&index=1&md
July 11, 15:50
Viromed Medical AG Seeks Special Approval for Cold Plasma Device for the Prevention of Ventilator-Associated Pneumonia (VAP)
Viromed Medical AG (ISIN: DE000A3MQR65; “Viromed”) is launching a second pioneering study on the use of cold plasma for the prevention of ventilator-associated pneumonia (VAP). The study, under the sc
Merz Therapeutics Closes $185M Asset Purchase Agreement with Acorda Therapeutics
July 11, 11:41
Merz Therapeutics Closes $185M Asset Purchase Agreement with Acorda Therapeutics
Merz Therapeutics announces today the successful acquisition of INBRIJA® (levodopa inhalation powder) and (F)AMPYRA® (fampridine), and related assets from Acorda Therapeutics, Inc. AMPYRA® (dalfamprid
July 10, 15:56
Brandnew Lab launches three ‘Nuvoen’ ampoule series for clinics
Brandnew Lab announced that it has launched three ampoule products - Boost, Lipo, and PLLA - under its clinic solution brand ‘Nuvoen’, which has the slogan ‘bring new vitality to the skin’, on July 10
July 10, 15:25
MMI Builds Global Momentum with Multiple Distribution Agreements and Regulatory Approvals
MMI (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.mmimicro.com%2F&esheet=54090621&newsitemid=20240709821670&lan=en-US&anchor=MMI&index=1&md5=df42141cdf355f8be68a32aeb0578189)
DRX-Evolution Plus (Photo: Business Wire)
July 04, 14:10
Enhancing Technologist Experience and Patient Workflow, Carestream Reveals New Enhancements to CARESTREAM DRX-Evolution Plus System and ImageView Software
Carestream Health announced today the addition of new enhancements to its ImageView Software and DRX-Evolution Plus System, marking the latest improvements to its line of innovative, industry-leading
July 04, 10:50
Delta-Fly Pharma Inc.: Notice of initiation of patients enrollment in Phase III Pivotal comparative clinical trial of DFP-14323
We are excited to share our latest development status. We are pleased to announce that the enrollment of patients in the Phase III clinical trial of DFP-14323 in combination with Afatinib (20 mg/da
July 01, 16:35
TauRx Submits UK Marketing Authorisation Application for HMTM as a Treatment for Alzheimer’s Disease
TauRx Pharmaceuticals Ltd, a global leader in tau-based research in Alzheimer’s disease (AD), has announced the submission of a UK Marketing Authorisation Application (MAA) for hydromethylthionine mes
Left to right: Mitchell Rubin, Medisca CFO | Assemblyman Billy Jones | Stephane Nizri, Medisca Head
June 28, 14:10
Medisca Opens New Pharmaceutical Repackaging Facility to Meet Global Demands in Personalized Medicine
Medisca, a global leader in personalized pharmaceutical solutions, held a grand opening event on June 20, 2024, for their new repackaging and distribution facility in Plattsburgh, New York. The event
QPS Missouri, a division of QPS Holdings, LLC, a global Contract Research Organization. QPS Missouri
June 28, 11:30
QPS Announces New Laboratory Services for Clinical Trials and Cell Therapy Development
QPS, a leading global contract research organization (CRO), is pleased to announce new laboratory services capabilities. The central laboratory, leukopak cell therapy facility, and enhanced PBMC capab
June 27, 14:20
Takeda Announces New Assignments of Directors
Takeda (TOKYO:4502/NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting and at the Audit and Supervisory Committee meeting, following the 148th Ordinary M
ENCell presented promising results from their First-in-Human Phase 1 clinical trial of the novel me
June 27, 13:58
ENCell Presents the Phase 1 Clinical Trial Results of EN001 for Charcot-Marie-Tooth Disease at the PNS conference
ENCell Co., Ltd., a biotech in South Korea specializing in Cell and Gene therapy (CGT), presented promising results from their First-in-Human Phase 1 clinical trial of the novel mesenchymal stem cell
Danilo Neri - Partner & Vice President Executive at PQE Group (Photo: PQE Group)
June 27, 13:20
PQE Group Launches AI and Data Analytics Division: Innovation in the Service of Life Science
PQE Group, a leading consultancy in the Life Science sector, announces the consolidation of its new Regulated Artificial Intelligence & Data Analytics division operating since the initiation of AI bas
June 26, 14:45
Kenvue Releases Inaugural Healthy Lives Mission Report
Kenvue Inc. (NYSE: KVUE) (“Kenvue” or the “Company”), the world’s largest pure-play consumer health company by revenue, today released its first-ever Healthy Lives Mission Report and shared how the Co
June 26, 12:00
RoslinCT Appoints Professor Sir Peter Mathieson and Alexander Vos as New Non-Executive Directors
RoslinCT, a leading cell and gene therapy Contract Development and Manufacturing Organisation (CDMO), is pleased to announce the appointment of Professor Sir Peter Mathieson MB BS (Hons), PhD, FRCP, F
25 per page50 per page75 per page100 per page